Recombinant VEGF

VEGF Bioassay is a bioluminescent cell-based assay to measure VEGF stimulation and KDR (VEGFR-2) inhibition using NFAT-RE as a readout. The assay overcomes many limitations of current endothelial cell proliferation assays and can be used for discovery and development of novel biologic therapies for either inducing or inhibiting the VEGF response. The KDR/NFAT-RE HEK293 Cells included are provided in a thaw-and-use format as cryopreserved cells that can be thawed, plated and used in an assay without cell propagation. These cells were engineered to express exogenous KDR as well as the NFAT response element (RE) upstream of Luc2P. When VEGF binds to KDR/NFAT-RE HEK293 Cells, the KDR transduces intracellular signals, resulting in NFAT-RE-mediated luminescence. The bioluminescent signal is detected and quantified using Bio-Glo Luciferase Assay System and a standard luminometer. Recombinant VEGF may be used as a positive control ligand in the VEGF Bioassay.